LEADER 01390nam  2200385Ia 450 
001 9910699262303321
005 20230902161820.0
035   $a(CKB)5470000002401282
035   $a(OCoLC)475551107
035   $a(EXLCZ)995470000002401282
100   $a20091208d1994      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aDose-response information to support drug registration$b[electronic resource]
210  1$a[Rockville, MD] :$c[U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research],$d[1994]
215   $a1 online resource (15 pages)
225 1 $aGuideline for industry ;$vICH-E4
300   $a"November 1994."
320   $aIncludes bibliographical reference (page 15).
410  0$aGuideline for industry ;$vICH-E 4.
606   $aDose-response relationship (Biochemistry)
606   $aDrug approval$zUnited States
615  0$aDose-response relationship (Biochemistry)
615  0$aDrug approval
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 12$aInternational Conference on Harmonisation.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699262303321
996   $aDose-response information to support drug registration$93151645
997   $aUNINA